• 主页
  • 查找结果
  • A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.

A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.

Annals of the Royal College of Surgeons of England (2014-05-02)
S J Ford, M R Bedford, W Pang, A Wood, T Iqbal, C Tselepis, O Tucker
摘要

The incidence of oesophageal adenocarcinoma (OAC) is rising dramatically and overall survival remains extremely poor. Iron has been shown to potentiate tumourigenesis in OAC, and iron chelation therapy demonstrates promise in vivo as an adjunct to neoadjuvant and palliative chemotherapy. OAC, however, has traditionally been associated with iron deficiency anaemia. The aim of this study was therefore to formally quantify the iron status of OAC patients in order to guide the design of future clinical trials involving iron chelation therapy. Demographic and cancer specific data were collected prospectively from all patients presenting with OAC and gastric adenocarcinoma (GAC). Patients had haemoglobin, serum iron, serum ferritin and serum transferrin receptor (sTfR) levels measured to assess systemic iron status. In addition, the sTfR/log ferritin (sTfR-F) index was calculated. Average haemoglobin, serum iron, serum ferritin, sTfR and sTfR-F index values for all patients presenting with OAC were within normal sex specific reference ranges. No statistical difference in iron status was observed between OAC patients presenting with resectable and advanced OAC. Patients with OAC are relatively iron replete compared with those presenting with GAC. Iron parameters were not significantly altered by standard neoadjuvant chemotherapy. Patients presenting with resectable or advanced OAC could be considered as candidates for a clinical trial of iron chelation therapy as an addition to standard neoadjuvant or palliative treatments.

材料
货号
品牌
产品描述

Sigma-Aldrich
铁, ≥99%, reduced, powder (fine)
Sigma-Aldrich
铁蛋白 来源于马脾脏, Type I, saline solution
Sigma-Aldrich
铁, powder, −325 mesh, 97%
Sigma-Aldrich
羰基铁, ≥97% Fe basis
Sigma-Aldrich
铁, powder, <10 μm, ≥99.9% trace metals basis
Sigma-Aldrich
铁, puriss. p.a., carbonyl-Iron powder, low in magnesium and manganese compounds, ≥99.5% (RT)
Sigma-Aldrich
铁, flakes, ≥99.99% trace metals basis
Sigma-Aldrich
铁, nanopowder, 35-45 nm particle size, 99.5% trace metals basis
Sigma-Aldrich
铁, granular, 10-40 mesh, >99.99% trace metals basis
Sigma-Aldrich
铁, chips, 99.98% trace metals basis
Sigma-Aldrich
铁, foil, thickness 0.1 mm, ≥99.9% trace metals basis
Sigma-Aldrich
铁蛋白 来源于人类肝脏, Type IV, 10 μg/mL
Sigma-Aldrich
铁, foil, thickness 0.25 mm, ≥99.99% trace metals basis
Sigma-Aldrich
铁蛋白 来源于人类脾脏, Type V, 10 μg/mL in 0.15 M NaCl, 10 mM Tris, pH 8.0, containing 0.1% sodium azide
Sigma-Aldrich
铁, wire, diam. 1.0 mm, ≥99.9% trace metals basis
Sigma-Aldrich
铁, carbon coated magnetic, nanopowder, 25 nm avg. part. size, 99.5% trace metals basis
Sigma-Aldrich
铁, wire, diam. 0.5 mm, ≥99.9% trace metals basis
Sigma-Aldrich
铁, rod, diam. 6.3 mm, 99.98% trace metals basis
铁, IRMM®, certified reference material, 0.5 mm wire
铁, foil, 300x300mm, thickness 0.1mm, hard, 99.5%
铁, foil, 0.2m coil, thickness 0.5mm, coil width 49mm, armco« soft ingot 99.8+%
铁, wire reel, 1m, diameter 0.025mm, as drawn, 99.99+%
铁, wire reel, 20m, diameter 0.125mm, hard, 99.5%
铁, foil, 10mm disks, thickness 0.01mm, 99.85%
铁, foil, 10mm disks, thickness 0.01mm, 99.99+%
铁, foil, 10mm disks, thickness 0.020mm, 99.85%
铁, foil, 10mm disks, thickness 0.025mm, as rolled, 99.99+%
铁, foil, 10mm disks, thickness 0.025mm, hard, 99.5%
铁, foil, 10mm disks, thickness 0.038mm, hard, 99.5%
铁, foil, 10mm disks, thickness 0.05mm, as rolled, 99.99+%

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。